What does zmax look like

This is a decision you and your doctor will make. For this medicine, the following should be considered:. Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Appropriate studies have not been performed on the relationship of age to the effects of azithromycin to treat sinusitis in children or to treat pneumonia in children younger than 6 months of age. Safety and efficacy have not been established in these age groups. Appropriate studies have not been performed on the relationship of age to the effects of azithromycin oral suspension and tablets to treat pharyngitis or tonsillitis in children younger than 2 years of age.

Safety and efficacy have not been established. Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of azithromycin in the elderly. However, elderly patients are more likely to have heart rhythm problems eg, torsades de pointes which may require caution in patients receiving azithromycin.

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur.

In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive. Using this medicine with any of the following medicines is not recommended.

Your doctor may decide not to treat you with this medication or change some of the other medicines you take. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur.

Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco. The presence of other medical problems may affect the use of this medicine.

Make sure you tell your doctor if you have any other medical problems, especially:. Take this medicine only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. This medicine comes with a patient information leaflet. Read and follow the instructions carefully. Ask your doctor if you have any questions. Measure your dose correctly with a marked measuring spoon, oral syringe, or medicine cup.

The average household teaspoon may not hold the right amount of liquid. Dose adjustment of cyclosporine may be necessary; monitor cyclosporine serum concentrations during use with azithromycin and after discontinuation of azithromycin.

Dasatinib: Major Avoid coadministration of azithromycin with dasatinib due to the increased risk of QT prolongation. In vitro studies have shown that dasatinib has the potential to prolong cardiac ventricular repolarization prolong QT interval.

Degarelix: Major Avoid coadministration of azithromycin with degarelix due to the increased risk of QT prolongation. Androgen deprivation therapy i. Desflurane: Major Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation.

Halogenated anesthetics can prolong the QT interval. Desipramine: Major Avoid coadministration of azithromycin with tricyclic antidepressants TCAs due to the increased risk of QT prolongation. Desogestrel; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.

It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora.

One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs.

Antituberculous drugs e. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives.

These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances.

Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries e. Deutetrabenazine: Major Avoid coadministration of azithromycin with deutetrabenazine due to the increased risk of QT prolongation. Deutetrabenazine may prolong the QT interval, but the degree of QT prolongation is not clinically significant when deutetrabenazine is administered within the recommended dosage range.

Dextromethorphan; Quinidine: Major Avoid coadministration of azithromycin with quinidine due to the increased risk of QT prolongation.

Quinidine administration is associated with QT prolongation and TdP. Dienogest; Estradiol valerate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Digoxin: Moderate Monitor digoxin concentrations before and during concomitant use of azithromycin and reduce the digoxin dose if necessary. Elevated digoxin concentrations have been observed when azithromycin has been coadministered with digoxin.

Dihydroergotamine: Minor Carefully monitor patients when azithromycin and dihydroergotamine are used concomitantly. Disopyramide: Major Avoid coadministration of azithromycin with disopyramide due to the increased risk of QT prolongation. Disopyramide is associated with QT prolongation and TdP.

Dofetilide: Major Avoid coadministration of azithromycin with dofetilide due to the increased risk of QT prolongation. Dolasetron: Major Avoid coadministration of azithromycin with dolasetron due to the increased risk of QT prolongation.

Dolutegravir; Rilpivirine: Major Avoid coadministration of azithromycin with rilpivirine due to the increased risk of QT prolongation. Donepezil: Major Avoid coadministration of azithromycin with donepezil due to the increased risk of QT prolongation. Case reports indicate that QT prolongation and TdP can occur during donepezil therapy.

Donepezil; Memantine: Major Avoid coadministration of azithromycin with donepezil due to the increased risk of QT prolongation.

Doxepin: Major Avoid coadministration of azithromycin with tricyclic antidepressants TCAs due to the increased risk of QT prolongation. Dronedarone: Contraindicated Coadministration of dronedarone and azithromycin is contraindicated due to the potential for QT prolongation and torsade de pointes TdP.

There have been case reports of QT prolongation and TdP with the use of azithromycin in post-marketing reports. Dronedarone administration is associated with a dose-related increase in the QTc interval.

The increase in QTc is approximately 10 milliseconds at doses of mg twice daily the FDA-approved dose and up to 25 milliseconds at doses of mg twice daily. Although there are no studies examining the effects of dronedarone in patients receiving other QT prolonging drugs, coadministration of such drugs may result in additive QT prolongation.

Droperidol: Major Avoid coadministration of azithromycin with droperidol due to the increased risk of QT prolongation. Initiate droperidol at a low dose and increase the dose as needed to achieve the desired effect. Droperidol administration is associated with an established risk for QT prolongation and TdP. Some cases have occurred in patients with no known risk factors for QT prolongation and some cases have been fatal. Drospirenone: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.

Drospirenone; Estetrol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Drospirenone; Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Drospirenone; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.

Drospirenone; Ethinyl Estradiol; Levomefolate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.

Efavirenz: Major Avoid coadministration of azithromycin with efavirenz due to the increased risk of QT prolongation. QTc prolongation has been observed with the use of efavirenz. Efavirenz; Emtricitabine; Tenofovir: Major Avoid coadministration of azithromycin with efavirenz due to the increased risk of QT prolongation. Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate: Major Avoid coadministration of azithromycin with efavirenz due to the increased risk of QT prolongation.

Elagolix; Estradiol; Norethindrone acetate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Eliglustat: Major Avoid coadministration of azithromycin with eliglustat due to the increased risk of QT prolongation.

Emtricitabine; Rilpivirine; Tenofovir alafenamide: Major Avoid coadministration of azithromycin with rilpivirine due to the increased risk of QT prolongation. Emtricitabine; Rilpivirine; Tenofovir disoproxil fumarate: Major Avoid coadministration of azithromycin with rilpivirine due to the increased risk of QT prolongation.

Encorafenib: Major Avoid coadministration of azithromycin with encorafenib due to the increased risk of QT prolongation. Encorafenib is associated with dose-dependent prolongation of the QT interval. Enflurane: Major Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation. Entrectinib: Major Avoid coadministration of azithromycin with entrectinib due to the increased risk of QT prolongation.

Entrectinib has been associated with QT prolongation. Ergotamine: Minor Carefully monitor patients when azithromycin and ergotamine are used concomitantly. Ergotamine; Caffeine: Minor Carefully monitor patients when azithromycin and ergotamine are used concomitantly.

Eribulin: Major Avoid coadministration of azithromycin with eribulin due to the increased risk of QT prolongation. Eribulin has been associated with QT prolongation.

Escitalopram: Major Avoid coadministration of azithromycin with escitalopram due to the increased risk of QT prolongation. Escitalopram has been associated with a risk of QT prolongation and TdP. Estradiol; Levonorgestrel: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.

Estradiol; Norethindrone: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Estradiol; Norgestimate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.

Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Ethinyl Estradiol; Levonorgestrel; Folic Acid; Levomefolate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Ethinyl Estradiol; Norelgestromin: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.

Ethinyl Estradiol; Norethindrone Acetate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Ethinyl Estradiol; Norgestrel: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.

Ethynodiol Diacetate; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Etonogestrel; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Ezogabine: Major Avoid coadministration of azithromycin with ezogabine due to the increased risk of QT prolongation.

Ezogabine has been associated with QT prolongation. Fingolimod: Major Avoid coadministration of azithromycin with fingolimod due to the increased risk of QT prolongation. If concomitant use is unavoidable, overnight monitoring with continuous ECG in a medical facility is advised after the first dose of fingolimod; monitor ECG closely throughout therapy, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances.

Fingolimod initiation results in decreased heart rate and may prolong the QT interval. Fingolimod has not been studied in patients treated with drugs that prolong the QT interval, but drugs that prolong the QT interval have been associated with cases of TdP in patients with bradycardia.

Flecainide: Major Avoid coadministration of azithromycin with flecainide due to the increased risk of QT prolongation.

Although causality for TdP has not been established for flecainide, patients receiving concurrent drugs which have the potential for QT prolongation, such as azithromycin, may have an increased risk of developing proarrhythmias. Fluconazole: Major Avoid coadministration of azithromycin with fluconazole due to the increased risk of QT prolongation. Fluconazole has been associated with QT prolongation and rare cases of TdP.

Fluoxetine: Major Avoid coadministration of azithromycin with fluoxetine due to the increased risk of QT prolongation. QT prolongation and TdP have been reported in patients treated with fluoxetine.

Fluphenazine: Major Avoid coadministration of azithromycin with fluphenazine due to the increased risk of QT prolongation. Fluphenazine is associated with a possible risk for QT prolongation. Theoretically, fluphenazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation. Fluticasone; Salmeterol: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation.

Fluticasone; Umeclidinium; Vilanterol: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. Fluticasone; Vilanterol: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. Fluvoxamine: Major Avoid coadministration of azithromycin with fluvoxamine due to the increased risk of QT prolongation. QT prolongation and TdP have been reported during fluvoxamine postmarketing use.

Formoterol: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. Formoterol; Mometasone: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation.

Foscarnet: Major Avoid coadministration of azithromycin with foscarnet due to the increased risk of QT prolongation. Both QT prolongation and TdP have been reported during postmarketing use of foscarnet. Fosphenytoin: Minor Until more data are available, the manufacturer of azithromycin recommends caution and careful monitoring of patients who receive azithromycin with fosphenytoin.

Azithromycin was not implicated in clinical trials with drug interactions with fosphenytoin. However, specific drug interaction studies have not been performed with the combination of azithromycin and fosphenytoin. Fostemsavir: Major Avoid coadministration of azithromycin with fostemsavir due to the increased risk of QT prolongation. Supratherapeutic doses of fostemsavir 2, mg twice daily, four times the recommended daily dose have been shown to cause QT prolongation. Fostemsavir causes dose-dependent QT prolongation.

Gemifloxacin: Major Avoid coadministration of azithromycin with gemifloxacin due to the increased risk of QT prolongation. Gemifloxacin may also prolong the QT interval in some patients. The maximal change in the QTc interval occurs approximately 5 to 10 hours following oral administration of gemifloxacin. The likelihood of QTc prolongation may increase with increasing dose of the drug; therefore, the recommended dose should not be exceeded especially in patients with renal or hepatic impairment where the Cmax and AUC are slightly higher.

Gemtuzumab Ozogamicin: Major Avoid coadministration of azithromycin with gemtuzumab due to the increased risk of QT prolongation. Although QT interval prolongation has not been reported with gemtuzumab, it has been reported with other drugs that contain calicheamicin.

Gilteritinib: Major Avoid coadministration of azithromycin with gilteritinib due to the increased risk of QT prolongation. Gilteritinib has been associated with QT prolongation. Glasdegib: Major Avoid coadministration of azithromycin with glasdegib due to the increased risk of QT prolongation. Glasdegib therapy may result in QT prolongation and ventricular arrhythmias including ventricular fibrillation and ventricular tachycardia.

Glycopyrrolate; Formoterol: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. Goserelin: Major Avoid coadministration of azithromycin with goserelin due to the increased risk of QT prolongation. Granisetron: Major Avoid coadministration of azithromycin with granisetron due to the increased risk of QT prolongation. Granisetron has been associated with QT prolongation. Halogenated Anesthetics: Major Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation.

Haloperidol: Major Avoid coadministration of azithromycin with haloperidol due to the increased risk of QT prolongation. Excessive doses particularly in the overdose setting or IV administration of haloperidol may be associated with a higher risk of QT prolongation. Halothane: Major Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation.

Histrelin: Major Avoid coadministration of azithromycin with histrelin due to the increased risk of QT prolongation. Hydroxychloroquine: Major Avoid coadministration of hydroxychloroquine and azithromycin due the risk of additive QT prolongation.

Hydroxychloroquine prolongs the QT interval. QT prolongation and torsade de pointe TdP have been spontaneously reported during azithromycin postmarketing surveillance. Hydroxyzine: Major Avoid coadministration of azithromycin with hydroxyzine due to the increased risk of QT prolongation. Postmarketing data indicate that hydroxyzine causes QT prolongation and TdP.

Ibutilide: Major Avoid coadministration of azithromycin with ibutilide due to the increased risk of QT prolongation. Ibutilide administration can cause QT prolongation and TdP; proarrhythmic events should be anticipated.

The potential for proarrhythmic events with ibutilide increases with the coadministration of other drugs that prolong the QT interval. Iloperidone: Major Avoid coadministration of azithromycin with iloperidone due to the increased risk of QT prolongation. Iloperidone has been associated with QT prolongation. Imipramine: Major Avoid coadministration of azithromycin with tricyclic antidepressants TCAs due to the increased risk of QT prolongation.

Indacaterol: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation.

Indacaterol; Glycopyrrolate: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. Inotuzumab Ozogamicin: Major Avoid coadministration of inotuzumab ozogamicin with azithromycin due to the potential for additive QT interval prolongation and risk of torsade de pointes TdP. If coadministration is unavoidable, obtain an ECG and serum electrolytes prior to the start of treatment, after treatment initiation, and periodically during treatment.

Avoid any non-essential QT prolonging drugs and correct electrolyte imbalances. Inotuzumab has been associated with QT interval prolongation. QT prolongation and TdP have been spontaneously reported during azithromycin postmarketing surveillance.

Ipratropium; Albuterol: Major Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. Isoflurane: Major Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation. Itraconazole: Major Avoid coadministration of azithromycin with itraconazole due to the increased risk of QT prolongation.

Itraconazole has been associated with prolongation of the QT interval. Ivosidenib: Major Avoid coadministration of azithromycin with ivosidenib due to an increased risk of QT prolongation.

An interruption of therapy and dose reduction of ivosidenib may be necessary if QT prolongation occurs. Prolongation of the QTc interval and ventricular arrhythmias have been reported in patients treated with ivosidenib. Ketoconazole: Major Avoid coadministration of azithromycin with ketoconazole due to the increased risk of QT prolongation. Ketoconazole has been associated with prolongation of the QT interval. Lapatinib: Major Avoid coadministration of azithromycin with lapatinib due to the increased risk of QT prolongation.

Lapatinib has been associated with concentration-dependent QT prolongation; ventricular arrhythmias and TdP have been reported in postmarketing experience with lapatinib.

Lefamulin: Major Avoid coadministration of azithromycin with lefamulin as concurrent use may increase the risk of QT prolongation. Lefamulin has a concentration dependent QTc prolongation effect. The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between lefamulin and other drugs that effect cardiac conduction is unknown. Lenvatinib: Major Avoid coadministration of azithromycin with lenvatinib due to the increased risk of QT prolongation.

Prolongation of the QT interval has been reported with lenvatinib therapy. Leuprolide: Major Avoid coadministration of azithromycin with leuprolide due to the increased risk of QT prolongation.

Leuprolide; Norethindrone: Major Avoid coadministration of azithromycin with leuprolide due to the increased risk of QT prolongation. Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Levalbuterol: Major Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation.

Levofloxacin: Major Avoid coadministration of azithromycin with levofloxacin due to the increased risk of QT prolongation. Levofloxacin has been associated with a risk of QT prolongation and TdP.

Although extremely rare, TdP has been reported during postmarketing surveillance of levofloxacin. Levonorgestrel: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.

Levonorgestrel; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Levonorgestrel; Ethinyl Estradiol; Ferrous Bisglycinate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.

Lithium: Major Avoid coadministration of azithromycin with lithium due to the increased risk of QT prolongation. Lithium has also been associated with QT prolongation. Lofexidine: Major Avoid coadministration of azithromycin with lofexidine due to the increased risk of QT prolongation.

Lofexidine prolongs the QT interval. Long-acting beta-agonists: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation.

Loperamide: Major Avoid coadministration of azithromycin with loperamide due to the increased risk of QT prolongation. At high doses, loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, TdP, and cardiac arrest.

Loperamide; Simethicone: Major Avoid coadministration of azithromycin with loperamide due to the increased risk of QT prolongation. Lopinavir; Ritonavir: Major Avoid coadministration of azithromycin with lopinavir; ritonavir due to the increased risk of QT prolongation. Lopinavir; ritonavir is associated with QT prolongation. Macimorelin: Major Avoid coadministration of azithromycin with macimorelin due to the increased risk of QT prolongation and torsade de pointes-type ventricular tachycardia.

Sufficient washout time of drugs that are known to prolong the QT interval prior to administration of macimorelin is recommended. Treatment with macimorelin has been associated with an increase in the corrected QT QTc interval. Maprotiline: Major Avoid coadministration of azithromycin with maprotiline due to the increased risk of QT prolongation.

Maprotiline has been reported to prolong the QT interval, particularly in overdose or with higher-dose prescription therapy elevated serum concentrations. Cases of long QT syndrome and TdP tachycardia have been described with maprotiline use, but rarely occur when the drug is used alone in normal prescribed doses and in the absence of other known risk factors for QT prolongation.

Limited data are available regarding the safety of maprotiline in combination with other QT-prolonging drugs. Mefloquine: Major Avoid coadministration of azithromycin with mefloquine due to the increased risk of QT prolongation.

There is evidence that the use of halofantrine after mefloquine causes a significant lengthening of the QTc interval. Mefloquine alone has not been reported to cause QT prolongation. Meperidine; Promethazine: Major Avoid coadministration of azithromycin with promethazine due to the increased risk of QT prolongation.

Mestranol; Norethindrone: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Metaproterenol: Major Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation.

Methadone: Major Avoid coadministration of azithromycin with methadone due to the increased risk of QT prolongation. Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction.

Midostaurin: Major Avoid coadministration of azithromycin with midostaurin due to the increased risk of QT prolongation. QT prolongation was reported in patients who received midostaurin in clinical trials. Mifepristone: Major Avoid coadministration of azithromycin with mifepristone due to the increased risk of QT prolongation. Mifepristone has been associated with dose-dependent prolongation of the QT interval.

Mirtazapine: Major Avoid coadministration of azithromycin with mirtazapine due to the increased risk of QT prolongation. Mirtazapine has been associated with dose-dependent prolongation of the QT interval.

TdP has been reported postmarketing, primarily in overdose or in patients with other risk factors for QT prolongation. Moxifloxacin: Major Avoid coadministration of azithromycin with moxifloxacin due to the increased risk of QT prolongation. Quinolones have been associated with a risk of QT prolongation. Although extremely rare, TdP has been reported during postmarketing surveillance of moxifloxacin. These reports generally involved patients with concurrent medical conditions or concomitant medications that may have been contributory.

Nelfinavir: Moderate Coadministration of nelfinavir and azithromycin results in increased azithromycin concentrations. Dosage adjustments are not necessary, although patients should be monitored for azithromycin related adverse effects such as increased hepatic enzymes and hearing impairment.

Nilotinib: Major Avoid coadministration of azithromycin with nilotinib due to the increased risk of QT prolongation. Sudden death and QT prolongation have been reported in patients who received nilotinib therapy. Norethindrone Acetate; Ethinyl Estradiol; Ferrous fumarate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.

Norethindrone: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Norethindrone; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Norethindrone; Ethinyl Estradiol; Ferrous fumarate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.

Norgestimate; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Norgestrel: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.

Nortriptyline: Major Avoid coadministration of azithromycin with tricyclic antidepressants TCAs due to the increased risk of QT prolongation. Octreotide: Major Avoid coadministration of azithromycin with octreotide due to the increased risk of QT prolongation. Arrhythmias, sinus bradycardia, and conduction disturbances have occurred during octreotide therapy. Since bradycardia is a risk factor for development of TdP, the potential occurrence of bradycardia during octreotide administration could theoretically increase the risk of TdP in patients receiving drugs that prolong the QT interval.

Ofloxacin: Major Avoid coadministration of azithromycin with ofloxacin due to the increased risk of QT prolongation. Quinolones have been associated with a risk of QT prolongation and TdP.

Although extremely rare, TdP has been reported during postmarketing surveillance of ofloxacin. Olanzapine: Major Avoid coadministration of azithromycin with olanzapine due to the increased risk of QT prolongation.

Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval. Olanzapine; Fluoxetine: Major Avoid coadministration of azithromycin with fluoxetine due to the increased risk of QT prolongation.

Major Avoid coadministration of azithromycin with olanzapine due to the increased risk of QT prolongation. This medication may also cause a decrease in liver function. If you experience symptoms of liver problems such as fatigue, feeling unwell, loss of appetite, nausea, yellowing of the skin or whites of the eyes, dark urine, pale stools, abdominal pain or swelling, and itchy skin, contact your doctor immediately.

Myasthenia gravis: Myasthenia gravis is a condition that causes specific muscle weakness. Azithromycin may cause the symptoms of myasthenia gravis to flare up. If you have myasthenia gravis, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed. Overgrowth of organisms: Prolonged or repeated use of azithromycin may result in an overgrowth of bacteria or fungi and organisms that are not killed by the medication.

This can cause other infections, such as yeast infections, to develop. Pregnancy: The safety of azithromycin for use by pregnant women has not been established.

This medication should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking this medication, contact your doctor immediately. Breast-feeding: This medication passes into breast milk. If you are a breast-feeding mother and are taking azithromycin it may affect your baby.

Talk to your doctor about whether you should continue breast-feeding. Children: The safety and efficacy of azithromycin tablets or suspension have not been established for treating children younger than 6 months of age who have acute otitis media or community-acquired pneumonia. The safety and efficacy of azithromycin tablets or suspension have not been established for treating children younger than 2 years of age who have throat infections or tonsillitis.

The safety and efficacy of azithromycin injection have not been established for children less than 16 years of age.

If you are taking any of these medications, speak with your doctor or pharmacist. Depending on your specific circumstances, your doctor may want you to:.

An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed. Medications other than those listed above may interact with this medication. Tell your doctor or prescriber about all prescription, over-the-counter non-prescription , and herbal medications that you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them.

All material copyright MediResource Inc. Terms and conditions of use. The contents herein are for informational purposes only. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Source: www. About this Medication. How does this medication work? What will it do for me? Sponsored Health Tool. Facts vs. Myths: Pneumococcal disease. Get the facts. Your pneumococcal vaccine options. Learn more.